JNJ - Johnson & Johnson
147.07 -0.12 (-0.08%)
After hours: 7:28PM EDT
Chart Events
Williams %R
Performance Outlook
- Short Term2W - 6W
- Mid Term6W - 9M
- Long Term9M+
| Previous Close | 148.75 |
| Open | 147.29 |
| Bid | 147.00 x 1000 |
| Ask | 147.19 x 1100 |
| Day's Range | 146.01 - 148.34 |
| 52 Week Range | 109.16 - 157.00 |
| Volume | 5,724,035 |
| Avg. Volume | 11,532,026 |
| Market Cap | 388.044B |
| Beta (5Y Monthly) | 0.72 |
| PE Ratio (TTM) | 22.97 |
| EPS (TTM) | 6.41 |
| Earnings Date | Jul 16, 2020 |
| Forward Dividend & Yield | 4.04 (2.72%) |
| Ex-Dividend Date | May 22, 2020 |
| 1y Target Est | 164.17 |
Fair Value
Related Research
- MarketWatch
Why virus stocks are driving market volatility
The market’s erratic response to lukewarm medical research for COVID-19 treatment and vaccine candidates isn’t expected to slow down as investors pin their hopes for an economic recovery on the high-risk biotechnology sector.
- Motley Fool
If You Invested $10,000 in Johnson & Johnson’s IPO, This Is How Much Money You'd Have Now
Wouldn't it have been great to get in on the ground floor of Johnson & Johnson? How much money would you have now if you had been in that group and invested $10,000 in J&J? Twenty years before Mick Jagger, Keith Richards, and the rest of the band released that song, Johnson & Johnson listed its shares on the New York Stock Exchange.
- Yahoo Finance Video
It was a relatively easy decision: J&J Exec shares experience working in the frontlines
New York City hospitals were slammed in April, known as the peak of the coronavirus crisis. Dr. Ed Kuffner, Johnson & Johnson Chief Medical Officer Consumer Companies joins Yahoo Finance’s On The Move panel to discuss the company’s search for a coronavirus vaccine.
- Investopedia
Best Dividend Stocks for June 2020
Given strong dividend growth and big money signals, these stocks could be worth a spot in a yield-oriented portfolio.
- Reuters
U.S. awards new $628 mln contract to boost output of potential COVID-19 vaccine
The U.S. government on Monday entered into a $628 million contract with drugmaker Emergent BioSolutions to boost manufacturing capacity for a potential COVID-19 vaccine. As drugmakers race to develop vaccines, tests and therapies for COVID-19, the United States is looking to secure manufacturing capacity under its "Operation Warp Speed" program announced in May to accelerate vaccine development. "Securing more manufacturing capacity here in America for candidates that make it to the final stages of Operation Warp Speed will help get a vaccine to American patients without a day wasted," Department of Health and Human Services (HHS) Secretary Alex Azar said in a statement.
- Motley Fool
Here’s How to Find the Best Dividend Stocks
Before putting your money in a dividend stock, you'll want to make sure it meets certain criteria. Let's look into how to identify great dividend stocks, and then we'll turn our attention to one stock that's a great choice for income-seeking investors. There are several dividend-specific metrics to consider when looking for great dividend stocks.
- MarketWatch
Revoking Hong Kong’s special status is Trump’s ‘nuclear option’ that could trigger irrevocable U.S.-China split, analysts warn
Secretary of State Mike Pompeo declared Hong Kong to be no longer autonomous from China Wednesday, a move that further increases U.S.-China tensions and could pave the way for changes to U.S. policy toward Hong Kong that could have massive ramifications for the Hong Kong, Chinese and American economies.
- GuruFocus.com
Alan Fournier Adds 4 Stocks to Portfolio
Guru releases 1st-quarter portfolio Continue reading...
- Reuters
J&J's Ebola vaccine wins EU regulatory panel backing
J&J submitted its application to the European Medicines Agency (EMA) in November for the vaccine, which targets an Ebola strain that causes the disease in most people. The company in February said it was developing a coronavirus vaccine program with the help of the same technologies used in the experimental Ebola vaccine. The panel recommendation confirms the potential of the vaccine technology, Johan Van Hoof, managing director of J&J's Janssen unit said.
- Investor's Business Daily
Is Johnson & Johnson Stock A Buy As Pressure Mounts For A Coronavirus Vaccine?
Johnson & Johnson is hoping to tackle the new form of coronavirus with a vaccine, but the pharma giant is still facing litigation challenges. Is JNJ stock a buy right now?
- Reuters
European agency panel recommends approval of J&J's Ebola vaccine
A panel of the European health regulator on Friday recommended approving Johnson & Johnson's two-dose experimental vaccine for Ebola in the European Union. J&J submitted its application to the European Medicines Agency (EMA) in November for its vaccine, which targets an Ebola strain that causes the virus in most people. The company in February said it was developing a coronavirus vaccine program that would utilize the same technologies used to make the experimental Ebola vaccine.
- Investor's Business Daily
Is Abbott Stock A Buy After Defending The Accuracy Of Coronavirus Test?
Medical company Abbott has now launched five coronavirus tests. It's expected to take a sizable share of the market. But researchers are questioning test accuracy. Is ABT stock a buy now?
- Yahoo Finance
ER doctor: 12-18 month coronavirus vaccine timeline 'is extremely optimistic'
As the fallout from the coronavirus pandemic continues, the search for a vaccine is not slowing down.
- MarketWatch
Dow climbs 69 points on gains in shares of Boeing, Merck
DOW UPDATE The Dow Jones Industrial Average is up Thursday morning with shares of Boeing and Merck leading the way for the blue-chip average. The Dow (DJIA) was most recently trading 69 points, or 0.3%, higher, as shares of Boeing (BA) and Merck (MRK) are contributing to the index's intraday rally.
- Investor's Business Daily
Is ISRG Stock A Buy After Coronavirus Slammed Quarterly Growth?
ISRG stock has skidded this year, leading Intuitive Surgical stock performance to lag its peers in its medical technology group. So, is it time to take on this robotic surgery stock?
- Barrons.com
A $39B Stock Fund Puts Dividends in Perspective During the Coronavirus Crisis
The Vanguard Dividend Growth fund may give companies a pass if they need to reduce or suspend their dividends during the coronavirus pandemic, a very different shift for a fund focused on payouts.
- Motley Fool
Is Johnson and Johnson Stock a Buy?
The healthcare giant's done well over the years, but will that continue amid its legal problems?
- Zacks
Johnson & Johnson (JNJ) Gains But Lags Market: What You Should Know
Johnson & Johnson (JNJ) closed at $144.89 in the latest trading session, marking a +0.23% move from the prior day.
- Motley Fool
5 Dividend Kings to Buy and Hold Forever
The "forever" part means investors have to think about the longevity of payout growth as well as reliable payments.
- TheStreet.com
Jim Cramer: We Have a Rip Snorting Rally Unfathomable 2 Months Ago
So what's the narrative? Simple: the recession is ending, it turned out to be a V recession and recovery after all.
- Yahoo Finance
Novavax expects COVID-19 vaccine trial results in July
Biotech firm Novavax has entered its coronavirus vaccine in a Phase 1 clinical trial in Australia — the first in the Southern Hemisphere.
- Insider Monkey
Hedge Funds Started Cashing Out Of Johnson & Johnson (JNJ) During The Crash
We at Insider Monkey have gone over 821 13F filings that hedge funds and prominent investors are required to file by the SEC The 13F filings show the funds' and investors' portfolio positions as of March 31st, near the height of the coronavirus market crash. In this article, we look at what those funds think […]
- Zacks
The Zacks Analyst Blog Highlights: Bristol-Myers, Roche, AstraZeneca, Merck and Johnson & Johnson
The Zacks Analyst Blog Highlights: Bristol-Myers, Roche, AstraZeneca, Merck and Johnson & Johnson
- Motley Fool
3 Dividend Stocks Ideal for Retirees
Dividend stocks are a great option for a retirement account since you're earning income simply for holding shares. The coronavirus pandemic caused many companies to cut or cancel dividends. While other businesses saw substantial revenue declines from the current economic slowdown, there were at least three that delivered revenue and dividend increases in these tough economic times.
- Bloomberg
The More Covid-19 Vaccines, the Merrier
(Bloomberg Opinion) -- The way the Covid-19 crisis ends is with vaccines — not a vaccine. More than one horse can win this race. Some of us might end up getting a shot of a more traditional vaccine, which uses parts of an inactivated virus to stimulate immunity. Others might get vaccines based on emerging technologies that use synthetic versions of the virus’s genetic code.One such novel candidate, based on RNA and made by Moderna, showed promising results in early human trials, though critics warned the evidence is preliminary. Meanwhile, a different prototype based on DNA made headlines for an experiment that showed it worked in monkeys.In the end, some vaccines might be extremely effective but harder to scale; others the opposite. Even a less-effective vaccine might work well enough to provide herd immunity in a wider population. Other vaccines might be more appropriate for health care workers, who have to risk exposure on the job, and need protection as soon as possible.Scientists have created more than 70 vaccine candidates so far. “If we end up with two, three, or four vaccines, that’s good, since we have seven billion people,” says Harvard vaccine researcher Dan Barouch, who led the development of one of the vaccines featured in recent news. His group began working on a vaccine in January, after the virus started spreading in China. There are good reasons for him and other scientists to be optimistic. “For Covid-19, it’s clear most humans who get infected recover … that alone shows the human immune system can eliminate the virus,” he says. That makes it a much easier target than HIV, which he calls unprecedented in the history of vaccinology for its ability to evade the immune system. And the SARS-Cov2 virus doesn’t have the fast mutation rate that makes flu viruses a moving target.Art Krieg, a physician and founder of Checkmate Pharmaceuticals, says he’s very optimistic that because the human immune system can successfully battle the virus, so will one or more of the many experimental vaccines. All vaccines have to provide a danger signal to “prime” the immune system into acting against an invader. In 1995, Krieg reported the discovery one of these danger signals — called CpG DNA — which has been used in several vaccines, including one for hepatitis B, and is in some of the experimental candidates against the virus that causes Covid-19.Next, the vaccine has to mimic the invader in order to get the immune system to create specific antibodies that target the intended enemy. Vaccine designers using genetic material (DNA or RNA) have to stimulate the immune system enough to generate those antibodies, but not so much that the immune system destroys the vaccine before it can complete its mission.The biggest driver of recent headlines (and stock market drama) was a vaccine produced by the Massachusetts-based company Moderna, which is based on synthetic genetic material identical to parts of the code carried by the coronavirus. The genetic material is RNA — the single-stranded cousin of DNA. (Other RNA vaccines are being studied by BionTech, Translate Bio, and Curevac.) The RNA tricks human cells into making proteins identical to the “spike” proteins the virus uses to penetrate human cells. And that, in turn, stimulates the immune system to make antibodies that will be ready to block that protein if the real coronavirus invades.The excitement about Moderna’s vaccine followed the release of data from a trial that involved 45 volunteers, though the company only described results for eight of them. Of the eight, all produced antibodies with the desired “neutralizing” property needed to attack the virus in the future. What happened to the other 37 people? Since this vaccine requires two doses, they probably just didn’t have that data yet, says Krieg.A similar concept is behind DNA vaccines. The one developed by Harvard’s Barouch made the news for a successful experiment in monkeys. Other DNA vaccines are already in early human trials, including candidates developed by Oxford University, Johnson & Johnson and the Chinese company CanSino Biologics.These DNA vaccines use synthetic strings of code for making the spike protein carried by the virus. In some of these, the synthetic DNA is injected alone, while in others, it rides into human cells inside a deactivated cold virus (called an adenovirus). The human cells transcribe the DNA to RNA, and then into the decoy spike protein used to create immunity to the real thing. While the prototype developed by Barouch’s group at Harvard can be given in two shots, the Oxford DNA vaccine and several others that use cold viruses confer immunity with just one shot, says Krieg. DNA and RNA aren’t our only options. Yet another vaccine concept, made by Dynavax, uses the spike protein itself and stimulates the immune system using a synthetic DNA danger signal — the CpG DNA. These protein-based vaccines would have to be produced in bulk in fermentation vats, which Krieg says is something the biotech industry is equipped to do.Krieg says all the novel vaccines work through the same well-established scientific principles, and are very likely to be safe. Still, he says, it’s well known that vaccines don’t work as well in the elderly and immunocompromised. Imperfect vaccines could still eradicate the virus through herd immunity but only if the bulk of the population gets vaccinated. Once the technical hurdles are overcome, there will be social hurdles — already, there are movements among anti-vaxxers to resist — but it’s not too soon to plan to surmount them.Barouch says the ordinarily competitive nature of science has changed, as everyone understands how much is at stake in terms of lives and economic damage. In retrospect, critics might be able to criticize approaches that didn’t work, but right now, we need all the ideas we can get.This column does not necessarily reflect the opinion of the editorial board or Bloomberg LP and its owners.Faye Flam is a Bloomberg Opinion columnist. She has written for the Economist, the New York Times, the Washington Post, Psychology Today, Science and other publications. She has a degree in geophysics from the California Institute of Technology.For more articles like this, please visit us at bloomberg.com/opinionSubscribe now to stay ahead with the most trusted business news source.©2020 Bloomberg L.P.
